Hybrid Closed-Loop Insulin Pump Shows Promise for Older Adults with Type 1 Diabetes

Researchers wanted to understand how well the MiniMed 780G system—a hybrid closed-loop insulin pump—works for older adults with type 1 diabetes. Hybrid closed-loop systems automate much of insulin delivery by combining a continuous glucose monitor, insulin pump, and algorithm that adjusts insulin doses in real time. Until now, most evidence for these systems came from studies in younger patients.

This randomised trial enrolled adults aged 65 and older who had lived with type 1 diabetes for many years and had other chronic health conditions. Participants used the MiniMed 780G system for 12 months while researchers tracked their blood sugar control, safety, and signs of vascular health using artificial intelligence to assess blood vessels in the eye.

The results showed substantial improvement in glycaemic management—a measure of how well blood sugar is controlled over time. Participants spent significantly more time with blood sugar in their target range: 57.4% at the start of the study compared to 79.7% after 12 months. This kind of improvement is meaningful because better time in range is associated with reduced long-term health complications.

These gains appeared quickly and held steady throughout the year, suggesting the system was consistently effective for this age group.

A key concern when testing new diabetes technologies in older adults is whether they are safe and tolerable, especially for people managing multiple health conditions. The MiniMed 780G system was found to be safe and well-tolerated over the 12-month period. There were no serious safety concerns that would raise red flags about use in this population.

Additionally, the study assessed blood vessel health in the eyes using advanced artificial intelligence imaging. Retinal vascular status remained stable throughout follow-up in both eyes, with no signs of improvement or harm.

People aged 65 and older with type 1 diabetes have historically been underrepresented in clinical trials of new insulin delivery systems. This study fills an important evidence gap by directly testing whether hybrid closed-loop technology benefits older adults—a group that may face unique challenges with diabetes management, including managing multiple medications and health conditions.

The results suggest that the MiniMed 780G system can be an effective option for glycaemic management in this age group. However, this was a single-centre trial, so larger studies in different settings would help confirm these findings. Anyone considering a hybrid closed-loop system should discuss their individual situation with their diabetes care team.

Source: Diabetologia. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.